For the study ... show. The findings were published Monday in the Annals of Internal Medicine. There has been a notable uptick in GLP-1 use since 2020, Rezaie noted. The U.S. Food and Drug ...

Semaglutide did not increase the risk of depression, suicidal thoughts or suicidal behavior in people without known mental ...

Liraglutide vs placebo reduced shrinking in the parts of the brain responsible for memory, learning, language, and decision-making by 50%.

A total of 77 suicide deaths in GLP-1 agonist users and 71 in SGLT2 inhibitor users were identified. Subgroup analyses ...

At least two in five U.S. adults under the age of 65 with "private insurance could be eligible under clinical criteria for GLP-1 drugs," a new KFF analysis shows.

Related Study shows shift in GLP-1 drug use for obesity, not diabetes Weight loss drug Zepbound outperforms Ozempic in new ...

Glucagon-like peptide-1 agonist drugs, such as semaglutide, could save countless lives at risk due to diabetes and obesity.

Aon found GLP-1 use cost employer health plans $6.25 per member per month in 2023, a 224% increase compared to 2022. The data on spending for 2024 is not yet available, but a study shows GLP-1 ...

although the latter also appeared to show monomerization of the semaglutide samples similar to the PAGE and SEC analyses. These findings help to build upon Lexaria’s growing dataset ...

GLP-1s, the newest class of obesity medications, have soared in popularity for their ability to help people lose weight. They may have additional health benefits, research shows. GLP-1 drugs have ...

Share on Pinterest The latest results from an Eli Lilly clinical trial show tirzepatide lowered the ... Images In a new clinical trial, the GLP-1 drug tirzepatide was effective in helping people ...

With demand for GLP-1 drugs sky-high ... asked drugmaker Lykos Therapeutics to run an additional study on the use of the psychedelic drug in patients with post-traumatic stress disorder, pushing ...